Background
==========

Exposure to dioxins causes a diverse spectrum of toxicities in humans and laboratory animals \[[@B1]-[@B4]\]. The fetus is one of the most sensitive targets of dioxins and a broad range of pathophysiological abnormalities, such as, disorders of brain development, thyroxin resistance, hepatic damage, hematopoietic disorders and lung dysfunction, are observed in humans after perinatal exposure to dioxins \[[@B1]\]. Dioxins are transferred to fetuses and infants through placentas and milk from mothers \[[@B5]\]. Dioxins were detected in all of the samples analyzed in a study performed using human umbilical cord or cord serum in Japan \[[@B6]\]. Higher dioxin levels were reported in the placenta compared to that in breast milk, in a study performed in Taiwan \[[@B7]\]. Not only the morphological and functional disorders brought about by the altered gene products but the comprehensive analyses of the change in gene expression are required to evaluate the effects of fetal exposure to endocrine disruptors \[[@B8]\]. However those studies of 2,3,7,8-tetrachlorodibenzo-*p*-dioxin (TCDD) on human feto-placentas are limited \[[@B6]-[@B13]\].

The amniotic membrane is of fetal origin but contains no blood vessels \[[@B14]\]. The amniotic epithelial cells (AEC) on the basement membrane which is the thickest among basement membranes in human lay in the most interior of the fetal membranes. From the histological character mentioned above, it is relatively easier to obtain homogenous cells for experiments without contamination of hematocytes or cells of blood vessel origin \[[@B15]\]. Moreover, since fetal membranes are the tissues disposed of after parturition, the ethical issues associated with use for experiments are limited. Therefore, we analyzed gene expression induced by TCDD, the most toxic congener among the dioxins, in primary cultures of human AEC using DNA microarray technology, a powerful tool in revealing global gene expression, and quantitative real-time PCR.

Methods
=======

Reagents
--------

2,3,7,8-TCDD was obtained from Cambridge Isotope Laboratory (Andover, MA). Human oligonucleotide glass array (Human Genome U133A Array) was from Affymetrix (Santa Clara, CA).

AEC culture and TCDD treatment
------------------------------

With the permission of The Internal Review Board for Gunma University Hospital and the written informed consent of the patients, we obtained fetal membrane samples from patients with single pregnancy without systemic disease, signs of premature delivery or fetal complications, during elective cesarean sections at term. Three fetal membranes from three women were used for independent primary cultures. AEC were prepared based on the method described by Okita et al \[[@B15]\] with slight modifications, after an amniotic membrane was mechanically peeled off from the chorion. Briefly, the membrane was incubated in 170 ml of Krebs-Ringer solution containing 0.15 % trypsin, 1.26 g/l sodium bicarbonate, 25 mM HEPES, 50 μg/ml streptomycin and 0.25 μg/ml amphotericin B at 37C using a Spinner Flask. The liberated cells were decanted at 30-min intervals and the incubation was performed seven times with freshly made trypsin solution. Each fraction of dispersed cells were centrifuged, resuspended in DME/Ham\'s F12 medium supplemented with 15 mM HEPES, 10% FBS, 50 μg/ml streptomycin and 0.25 μg/ml amphotericin B. The first fraction was discarded. The cell viability of the remaining fractions was determined by trypan blue exclusion and the fractions with viabilities not less than 80% were pooled. Cells were plated at the density of 2 × 10^6^cells per 25 cm^2^polystyrene flask in 10 ml of medium and cultured in a humidified atmosphere containing 5% CO~2~-- 95% air at 37C. The medium was changed every 2 to 3 days. The experiments were performed two weeks after plating when cells were sub-confluent to confluent. The cells were treated with 50 nM TCDD or DMSO (control), and further incubated for 48 hrs. Total RNA from these cells was isolated and used for DNA microarray and quantitative Real-Time PCR analyses.

DNA microarray
--------------

The microarray method was carried out according to the manufacture\'s instruction. Briefly, total RNA was extracted from the TCDD-treated cells and control AEC using an RNA extraction solution (Trizol). After Oligo-dT latex beads treatment, double stranded cDNA libraries were constructed from the mRNA of TCDD-treated cells and the control AEC using an oligo-dT primer with a T7-promoter sequence at the 5\'-end. Biotin-labeled complementary RNA was in vitro transcribed by T7 promoter using the cDNA libraries as template. The biotin-labeled RNA was fragmented. Each sample was hybridized to a separate oligonucleotide array (Affymetrix Human Genome U133A) for 16 hours at 45C, and then washed and stained with streptavidin phycoerythrin conjugate using GeneChip Fluidics. The arrays were scanned by a Gene-Array scanner using Affymetrix GeneChip Microarray Suite (MAS) 5.0 software for scanning and basic analysis.

The Human Genome U133A array contains 22,277 probe sets including 61 control probe sets, and analyzes the expression level of 18,720 full length transcripts with 13,900 characterized human genes. The arrays incorporate a perfect match (PM)/mismatch (MM) probe pair strategy. One probe from the pair perfectly matches its target sequence while the other contains a mismatch located at the center of the 25-mer sequence. This probe pairing design helps identify and subtract non-specific hybridization and background signal. For each probe pair, the MM signal was subtracted from the PM signal. The average of these differences was reflective of the level of expression of the gene. The global method of scaling/normalization was performed by MAS 5.0 software. A program (PathwayFinder) was used for pathway analysis. Three independent experiments were performed.

Quantitative real-time PCR
--------------------------

Messenger RNA was extracted using an RNA extraction solution (Trizol) and oligo-dT latex beads as described previously \[[@B15],[@B16]\]. Five micrograms of mRNA preparations were reverse-transcribed, and then converted to double stranded cDNA molecules. Complementary DNA was quantified by UV absorption measurement, and 1 ng was subjected to the PCR reaction as template. As an internal standard, TATA binding protein (TBP) was used instead of GAPDH, since GAPDH gene expression was affected by the TCDD treatment (data not shown). Quantitative real-time PCR was carried out in an ABI PRISM^®^7000 Sequence Detection System (Applied Biosystems; Foster City, CA), according to the manufacture\'s instructions. PCR reaction involved template cDNA samples, Advantage Taq Plus DNA polymerase (Clontech Laboratories, Inc.; Mountain View, CA), dNTP, and Syber Green. The thermal cycling conditions included an initial incubation of samples at 94°C for 2 min, followed by appropriate cycles of 94°C for 20 sec, 54°C for 30 sec and 72°C for 45 sec. Syber Green fluorescence was used to detect the amplified products. Serial dilutions of the templates were used to create a concentration curve, and relative expression levels were calculated using TBP as normalization control for each sample. Abundance of each gene was referred to as a Ct value in this system \[[@B16],[@B17]\]. Three independent experiments using AEC from three women were performed. Comparisons between the genes were performed using one-way ANOVA. The significance of the differences between the mean values of cytochromeP4501A1 (CYP1A1) and each gene was tested using paired *t*-test. P \< 0.05 was considered statistically significant.

Results
=======

Among the 22,277 genes spotted on the array, 12,509 genes were expressed in AEC population. Six hundred and ninety six TCDD-sensitive candidate genes were picked up; 326 were TCDD-inducible and 370 were TCDD-suppressive candidate genes (cut-off values of 1.9 as inducible and 0.5 as suppressive genes). Specific primers for 55 genes among 696 TCDD-sensitive candidate genes were synthesized (Table [1](#T1){ref-type="table"}). Those genes were selected for two reasons. One reason was that TCDD-sensitive genes in rat placenta had been examined previously \[[@B16]\]. In order to reveal the relationship of sensitive genes between rat placenta and AEC, those genes were selected. Another reason was that even the candidate genes might not represent actual sensitive genes, because false positive signals could not be excluded from the array data, especially when induction or suppression ratios were near 1.9 or 0.5. Therefore we selected genes with higher ratios for real-time PCR.

Genes that showed expression ratios (TCDD-treated/control) of more than 1.9 or less than 0.6 were finally identified as TCDD-sensitive. Among 55 genes analyzed, 38 genes were TCDD-inducible (Table [2](#T2){ref-type="table"}), 4 were -suppressive (Table [3](#T3){ref-type="table"}), and 13 were neither of them, by both DNA microarray technology and quantitative real-time PCR. TCDD-inducible genes were categorized into several groups. Enzyme genes include CYP1A1 and cytochromeP4501B1 (CYP1B1) which are known as the typical TCDD target genes. One of the remarkable findings of the present experiment was that many interferon-related genes were induced in TCDD-treated human AEC (Figure [1](#F1){ref-type="fig"}). The expression of interferon-inducible genes, that is, interferon induced transmembrane protein 1 (IFITM1), interferon, alpha-inducible protein (G1P2), interferon, alpha-inducible protein 27 (IFI27) and interferon-induced protein with tetratricopeptide repeats 1 (IFIT1) was strongly enhanced. The genes involved in the interferon gene expression and signaling pathway, that is, interferon regulatory factor 7 (IFR7), interferon-stimulated transcription factor 3, gamma 48 kDa (ISGF3G) and signal transducer and activator of transcription 1 (STAT1), were also up-regulated.

###### 

Primers used for quantitative real-time PCR

  Gene Name                                                                                                  Abbreviation                    Primers
  ---------------------------------------------------------------------------------------------------------- -------------- ---------------- -------------------------------
  Arylsulfatase B                                                                                            ARSB           Forward Primer   GTGGTGTGATCTCGGCTCACT
                                                                                                                            Reverse Primer   CGTGGTGGTGTATGCCTGTAAT
  Carbohydrate (N-acetylglucosamine 6-O) sulfotransferase 6                                                  CHST6          Forward Primer   GAAACTGAGTCCACCACTTGAGAA
                                                                                                                            Reverse Primer   TTATTGCTCCTAAAGTCTTCGACTTG
  Cytochrome P450 1A1                                                                                        CYP1A1         Forward Primer   AGCGGAAGTGTATCGGTGAGA
                                                                                                                            Reverse Primer   CTGAATTCCACCCGTTGCA
  Cytochrome P450 1B1                                                                                        CYP1B1         Forward Primer   AGCAGGCTTGCCCAGTACATT
                                                                                                                            Reverse Primer   AAATAGGCTACAGCAGCCCAAA
  Dehydrogenase/reductase (SDR family) member 2                                                              DHRS2          Forward Primer   TACTCATGCTAGGCTTGAGGAAGA
                                                                                                                            Reverse Primer   CACCAAGAACCCCACATGTTAA
  Fucosyltransferase 2 (secretor status included)                                                            FUT2           Forward Primer   CCAGTGTGCATACAGTCATGGA
                                                                                                                            Reverse Primer   CACGGTGCACTATATTCCCTAACTC
  GDP-mannose 4,6-dehydratase                                                                                GMDS           Forward Primer   GCCAAGGACTATGTGGAGGCTAT
                                                                                                                            Reverse Primer   ACAAATTCCCGGACACTATGGA
  Matrix metalloproteinase 9                                                                                 MMP9           Forward Primer   TTCCAGTACCGAGAGAAAGCCTAT
                                                                                                                            Reverse Primer   GGTCACGTAGCCCACTTGGT
  Membrane metallo-endopeptidase                                                                             MME            Forward Primer   ATTCCTTTGGGCCTCTGCTT
                                                                                                                            Reverse Primer   TGGGAAGGCAGCATTGGA
  Mitochondrial thioredoxin reductase                                                                        TXNRD2         Forward Primer   CTGAGGAAACTCTTATCAGAACATTACAC
                                                                                                                            Reverse Primer   GCGACGCGGTGCTACAA
  Podocalyxin-like                                                                                           PODXL          Forward Primer   GCAGAGAGGGCAAGAGTAAAACTG
                                                                                                                            Reverse Primer   GAGTCATCTGTGTCCTCCATGCT
  Poly (ADP-ribose) polymerase family, member 12                                                             ZC3HDC1        Forward Primer   TTCTCAGAGTCTCATGGCATCATAGT
                                                                                                                            Reverse Primer   GTCAGAACAACAGGCAGAAGTGA
  Stearoyl-CoA desaturase                                                                                    SCD            Forward Primer   AGGAATGTCCACCATGAACTTGATA
                                                                                                                            Reverse Primer   CACCGCTTCTCCAATGGATT
  Ubiquitin-conjugating enzyme E2E 1 (UBC4/5 homolog, yeast)                                                 UBE2E1         Forward Primer   GGTGGGAAGTATTGCCACTCA
                                                                                                                            Reverse Primer   GTGAAACCCCAATTTATGTAGCGTAT
  Uridine phosphorylase 1                                                                                    UPP1           Forward Primer   CGATTAAGAGACAGAGAATCTTGGATTA
                                                                                                                            Reverse Primer   GAAACCCCAAATCAGGCTAACA
  Interleukin 12B                                                                                            IL12B          Forward Primer   GACAAGTAGTTATGGCTAAGGACATGA
                                                                                                                            Reverse Primer   AGGGATTCCAGATTTTCTTTGCA
  Distal-less homeo box 2                                                                                    DLX2           Forward Primer   AGCCTGGACTTGGACACAGAGT
                                                                                                                            Reverse Primer   GGGTTGCTGAGGTCACTGCTA
  Early growth response 1                                                                                    EGR1           Forward Primer   AAGCCAAGCAAACCAATGGT
                                                                                                                            Reverse Primer   ACTCTGACACATGCTCTGAGAATACTG
  High mobility group AT-hook 1                                                                              HMGA1          Forward Primer   GTCCCCTACTCCCTCTTCACTGT
                                                                                                                            Reverse Primer   ACCTGGACAATAAGTGACTGCATCT
  Interferon regulatory factor 7                                                                             IFR7           Forward Primer   GCCTGGTCCTGGTGAAGCT
                                                                                                                            Reverse Primer   GAAGCACTCGATGTCGTCATAGA
  Interferon-stimulated transcription factor 3, gamma 48 kDa                                                 ISGF3G         Forward Primer   AAGTAGACTCATTCTTCACACGATTGAC
                                                                                                                            Reverse Primer   AGCCAGTGTGTGCGAGGATT
  Myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila); translocated to, 10 (MLLT10)   MLLT10         Forward Primer   GACCATTAAAAGCTCACCACTAGAGTTC
                                                                                                                            Reverse Primer   CTGCGGTACTGTCACATCAAAAG
  N-myc (and STAT) interactor (NMI)                                                                          NMI            Forward Primer   CGTGAAGATCAAATGAGAGACAAACT
                                                                                                                            Reverse Primer   CTCCCGGACTGTCTGTCATAGTC
  Nuclear antigen Sp100                                                                                      SP100          Forward Primer   CAGCTGTTTTGTTGACATTCTGAA
                                                                                                                            Reverse Primer   TGGAAGAAGACTGACCTGGTACCT
  Tumor necrosis factor, alpha-induced protein 3                                                             TNFAIP3        Forward Primer   GAGTAAATTGGCCTCTTTGATACACTT
                                                                                                                            Reverse Primer   AGGAGAAGCACGAAACATCGAT
  v-maf musculoaponeurotic fibrosarcoma oncogene homolog F (avian)                                           MAFF           Forward Primer   CCAGAAGGCAGAGGTTGTAGTGA
                                                                                                                            Reverse Primer   AGGAGCCGGGCAATATTTTTTA
  GABA-B receptor                                                                                            GPR51          Forward Primer   TGTGCGTCTGTAACCCTTTGTG
                                                                                                                            Reverse Primer   AATGGGTGAACCTACAGTATCAGTAAGA
  Interferon, alpha 1                                                                                        IFNA1          Forward Primer   TGATGAATGCGGACTCCATCT
                                                                                                                            Reverse Primer   GACAACCTCCCAGGCACAAG
  Signal transducer and activator of transcription 1                                                         STAT1          Forward Primer   TTGAGTGGATGATGTTTCGTGAA
                                                                                                                            Reverse Primer   AGAACCTTGTCAAACCCATCTCTT
  Solute carrier family 2 (facilitated glucose transporter), member 1                                        SLC2A1         Forward Primer   ACCACTGCAACGGCTTAGACTT
                                                                                                                            Reverse Primer   TGGGTAACAGGGATCAAACAGAT
  Solute carrier family 2 (facilitated glucose transporter), member 3                                        SLC2A3         Forward Primer   TTGCTCTGGGTGGAAGTACGTT
                                                                                                                            Reverse Primer   ACCAAGAAGGGAAAGGGAGACT
  Amphiregulin                                                                                               AREG           Forward Primer   GCTGCCTTTATGTCTGCTGTGA
                                                                                                                            Reverse Primer   CGTTCCTCAGCTTCTCCTTCA
  Caveolin 2                                                                                                 CAV2           Forward Primer   CTCATATCCTTTTGAAGGTAGTTGCA
                                                                                                                            Reverse Primer   GGTGATGCTTTAAGGTAATGATTATGC
  DnaJ (Hsp40) homolog, subfamily C, member 3                                                                DNALC3         Forward Primer   AAGAAGTTTGACGACGGAGAAGA
                                                                                                                            Reverse Primer   TTGAACCCTTGCCATGAGTTC
  Epiregulin                                                                                                 EREG           Forward Primer   CAATGTAACTCCACTGTTCTCCTGAA
                                                                                                                            Reverse Primer   CTGGTGGTGATTGAATTTAGTCTCA
  Epithelial membrane protein 1                                                                              EMP1           Forward Primer   AACTCTTGTGGTACCTAGTCAGATGGTA
                                                                                                                            Reverse Primer   GCAAAGCAATGCCTGCTTAAC
  FLJ20035                                                                                                   FLJ20035       Forward Primer   TAGTCCAGGATAACAGGATGAATGAA
                                                                                                                            Reverse Primer   ACATAGCTCACGCAAGGAAACA
  Insulin induced gene 1                                                                                     INSIG1         Forward Primer   AAGCTTAGAGGAACTTGCCTGTGA
                                                                                                                            Reverse Primer   TACTCCAAGACATTTCCCTCAAAAC
  Integrin, alpha 10                                                                                         ITGA10         Forward Primer   AGTAAAGGCAGTTGGATTCTCATAGAC
                                                                                                                            Reverse Primer   GAGCTGCACTCTGGAGACCAAT
  Integrin, alpha 2 (CD49B, alpha 2 subunit of VLA-2 receptor)                                               ITGA2          Forward Primer   AGATGATTTGGTCAGATTGGGATAAG
                                                                                                                            Reverse Primer   TGGGTGGTGTTTCTCAAAGTGT
  Interferon induced transmembrane protein 1                                                                 IFITM1         Forward Primer   TCCCTGTTCAACACCCTCTTCT
                                                                                                                            Reverse Primer   GTCACGTCGCCAACCATCTT
  Interferon, alpha-inducible protein                                                                        G1P2           Forward Primer   CCTGCTGGTGGTGGACAAAT
                                                                                                                            Reverse Primer   CCGCTCACTTGCTGCTTCA
  Interferon, alpha-inducible protein 27                                                                     IFI27          Forward Primer   TGGCCAGGATTGCTACAGTTG
                                                                                                                            Reverse Primer   TATGGAGGACGAGGCGATTC
  Interferon-induced protein with tetratricopeptide repeats 1                                                IFIT1          Forward Primer   GAAACTTCGGAGAAAGGCATTAGA
                                                                                                                            Reverse Primer   GCTCATAGTACTCCAGGGCTTCAT
  Interferon-induced protein with tetratricopeptide repeats 2                                                IFIT2          Forward Primer   CTTGGAACGATTGAGATTTTCTAGGT
                                                                                                                            Reverse Primer   CCCAGAGTGTGGCTGATGCT
  Keratin 6A                                                                                                 KRT6A          Forward Primer   TTCAGAACAACTTCCACTTACTTTCC
                                                                                                                            Reverse Primer   GTCACTTGTGCTTTCATGGATACTG
  Low density lipoprotein receptor-related protein 3                                                         LRP3           Forward Primer   CCCATCCTATGGTCAGCTCATC
                                                                                                                            Reverse Primer   CGTGCCGACGCATCTGT
  Presenilin 2 (Alzheimer disease 4)                                                                         PSEN2          Forward Primer   CACAGCAGGTTTATCCAGATGAAC
                                                                                                                            Reverse Primer   CACTCCCGAGCACACTCTTTG
  Ras-related associated with diabetes                                                                       RRAD           Forward Primer   TTGAGACATCAGCGGCATTG
                                                                                                                            Reverse Primer   CGTCGTGCGTTGGCTTCT
  Serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 2                                   SERPINB2       Forward Primer   GTGAATGAGGAGGGCACTGAAG
                                                                                                                            Reverse Primer   AGAAAAGGATGATCTGCCACAAAC
  Small proline-rich protein 3                                                                               SPRR3          Forward Primer   CCATGTCCTTCAACGGTCACT
                                                                                                                            Reverse Primer   AGCATCTGGTGGTTGGCTTCT
  Tripartite motif-containing 14                                                                             TRIM14         Forward Primer   GCAGAGACAGAGCTAGACTGTAAAGGT
                                                                                                                            Reverse Primer   CCTGGTCACACAATTGATATGGA
  Tumor necrosis factor                                                                                      TNF            Forward Primer   GAATGTGTGGCCTGCACAGT
                                                                                                                            Reverse Primer   CCAGATGTCAGGGATCAAAGC
  Chromosome 10 open reading frame 116                                                                       C10orf116      Forward Primer   ACAGCCTGGCCCTGATCTC
                                                                                                                            Reverse Primer   GCTTGCGAGGAATCATGAAGT
  Pleckstrin homology-like domain, family A, member 1                                                        PHLDA1         Forward Primer   ACGAGCACATTTCTATTGTCTTCACT
                                                                                                                            Reverse Primer   TCGCAAGTTTTCAGTAGGGTGAT

###### 

TCDD-inducible genes in human AEC

  Molecular function                    Gene Name                                                                  Array    Real Time   Ct      Accession
  ------------------------------------- -------------------------------------------------------------------------- -------- ----------- ------- ------------------------------
  Enzyme                                Carbohydrate (N-acetylglucosamine 6-O) sulfotransferase 6                  2.46     1.92        33.82   [NM_021615](NM_021615)
                                        Cytochrome P450 1A1                                                        6.79     10.36       20.74   [NM_000499](NM_000499)
                                        Cytochrome P450 1B1                                                        3.99     7.13        19.36   [NM_000104](NM_000104)
                                        Dehydrogenase/reductase (SDR family) member 2                              2.57     3.17        26.62   [NM_182908](NM_182908)
                                        Fucosyltransferase 2 (secretor status included)                            2.85     1.99        27.64   [NM_000511](NM_000511)
                                        Matrix metalloproteinase 9                                                 4.49     4.67        23.58   [NM_004994](NM_004994)
                                        Membrane metallo-endopeptidase                                             2.75     2.88        27.60   [NM_007287](NM_007287)
                                        Podocalyxin-like                                                           3.50     3.83        22.26   [NM_005397](NM_005397)
                                        Poly (ADP-ribose) polymerase family, member 12                             4.02     4.57        26.69   [NM_022750](NM_022750)
                                        Stearoyl-CoA desaturase                                                    2.56     2.06        27.95   [AB032261](AB032261)
                                        Uridine phosphorylase 1                                                    2.56     2.40        31.76   [NM_003364](NM_003364)
  Transcription Factor                  Distal-less homeo box 2                                                    3.05     2.50        24.50   [NM_004405](NM_004405)
                                        Interferon regulatory factor 7                                             2.82     4.46        25.21   [NM_004030](NM_004030)
                                        Interferon-stimulated transcription factor 3, gamma 48 kDa                 1.54     3.78        25.44   [NM_006084](NM_006084)
                                        N-myc (and STAT) interactor (NMI)                                          2.61     3.30        26.18   [NM_004688](NM_004688)
                                        Nuclear antigen Sp100                                                      1.06     2.28        29.04   [NM_003113](NM_003113)
                                        Tumor necrosis factor, alpha-induced protein 3                             2.50     2.18        25.94   [NM_006290](NM_006290)
                                        v-maf musculoaponeurotic fibrosarcoma oncogene homolog F (avian)           3.33     3.75        27.11   [NM_012323](NM_012323)
  Signal Transducer                     GABA-B receptor                                                            2.59     2.56        29.53   [AF056085](AF056085)
                                        Signal transducer and activator of transcription 1                         2.84     2.85        21.55   [NM_007315](NM_007315)
  Structural Protein and Other Groups   Amphiregulin                                                               2.80     10.70       22.56   [NM_001657](NM_001657)
                                        Epiregulin                                                                 4.18     3.19        27.35   [NM_001432](NM_001432)
                                        Epithelial membrane protein 1                                              3.01     2.84        25.54   [NM_001423](NM_001423)
                                        FLJ20035                                                                   11.16    5.58        30.53   [NM_017631](NM_017631)
                                        Insulin induced gene 1                                                     2.53     2.61        26.85   [NM_005542](NM_005542)
                                        Integrin, alpha 10                                                         2.72     1.91        25.04   [AF112345](AF112345)
                                        Integrin, alpha 2 (CD49B, alpha 2 subunit of VLA-2 receptor)               2.42     3.54        25.17   [NM_002203](NM_002203)
                                        Interferon induced transmembrane protein 1                                 5.31     31.85       27.24   [NM_003641](NM_003641)
                                        Interferon, alpha-inducible protein                                        12.65    18.72       21.80   [NM_005101](NM_005101)
                                        Interferon, alpha-inducible protein 27                                     12.13    16.84       23.13   [NM_005532](NM_005532)
                                        Interferon-induced protein with tetratricopeptide repeats 1                177.99   158.71      26.34   [NM_001001887](NM_001001887)
                                        Keratin 6A                                                                 3.23     4.45        21.99   [NM_005554](NM_005554)
                                        Ras-related associated with diabetes                                       2.72     2.42        23.57   [NM_004165](NM_004165)
                                        Serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 2   11.00    12.36       24.86   [NM_002575](NM_002575)
                                        Small proline-rich protein 3                                               2.97     3.56        22.33   [NM_005416](NM_005416)
                                        Tripartite motif-containing 14                                             4.61     2.56        27.43   [NM_014788](NM_014788)
                                        Tumor necrosis factor                                                      3.89     3.04        26.79   [NM_000594](NM_000594)
  Function Unknown                      Pleckstrin homology-like domain, family A, member 1                        2.81     5.13        27.91   [NM_007350](NM_007350)

###### 

TCDD-suppressive genes in human AEC

  Molecular function   Gene Name                                                             Array ratio   Real Time PCR ratio   Ct      Accession
  -------------------- --------------------------------------------------------------------- ------------- --------------------- ------- ------------------------
  Signal Transducer    Interferon, alpha 1                                                   5.03          0.22                  34.80   [NM_024013](NM_024013)
  Transporter          Solute carrier family 2 (facilitated glucose transporter), member 3   0.54          0.38                  23.13   [NM_006931](NM_006931)
  Structural Protein   Low density lipoprotein receptor-related protein 3                    2.69          0.56                  26.61   [NM_002333](NM_002333)
  Function Unknown     Chromosome 10 open reading frame 116                                  2.74          0.28                  33.78   [NM_006829](NM_006829)

![Induction of CYP1A1, CYP1B1 and interferon related genes in human AEC by TCDD. Expression levels were determined by DNA microarray and quantitative real-time PCR analyses as described in *Methods*. Values were expressed as fold induction (TCDD/control). The representative microarray data are shown as yellow columns. The values obtained by PCR analyses are shown as red columns. The data are shown as mean ± SD of three independent experiments. \*, P \< 0.05 compared with the value of CYP1A1.](1477-7827-4-27-1){#F1}

The other aspect in TCDD-treated human AEC was that integrin, alpha 10 (ITGA10), integrin, alpha 2 (ITGA2), and matrix metalloproteinase 9 (MMP9), which were genes involved in collagen synthesis and degradation, were also induced by TCDD treatment. However no changes in cellular morphology, number and viability were observed under the experimental conditions.

Discussion
==========

The amniotic membrane composes the innermost layer, nearest the fetus, of the fetal membranes containing the fetus and amniotic fluid \[[@B14]\]. It contains no blood vessels or nerves; the nutrients it requires are supplied by the amniotic fluid. The amniotic epithelium derived from epiblasts of embryo, laid in the most interior of the amniotic membrane, is in contact with amniotic fluid directly. The DNA microarray is a powerful and comprehensive method to identify inducible or suppressive genes by a given hormonal or pharmacological treatment. Using DNA microarray and quantitative real-time PCR technology, we analyzed TCDD-inducible genes in primary cultures of human AEC.

We measured gene expression after 48 hour incubation. Therefore early induced genes are not included in the present study. Biological persistence of TCDD is well known. It is reported that the expression of CYP1A1 mRNA was shown after 6 hours and sustained for up to 72 hours in human colon carcinoma cells treated with TCDD \[[@B18]\]. The maximum effect of TCDD on the expression of FSH receptor mRNA in rat granulosa cell cultures was shown after a 48 hour-incubation in our previous study \[[@B19]\]. The effect of TCDD on the expression of LH receptor mRNA was shown after 24 hours and sustained for up to 72 hours in the same cells \[[@B20]\]. Therefore, we studied TCDD-inducible genes in human AEC after a 48 hour-incubation.

The most striking observation in this experiment was that many interferon-inducible genes were prominently up-regulated in TCDD-treated human AEC; the increase of gene expression of IFITM1, G1P2, IFI27 and IFIT1 was equal to or far more than that of CYP1A1 and CYP1B1 which are well known as TCDD-inducible genes. The genes involved in the interferon gene expression and signaling pathway, that is, IFR7, ISGF3G and STAT1, were also up-regulated. The induction of interferon-related genes by TCDD was first reported by Mizutani et al., in the placentas of TCDD-treated Holtzman rats \[[@B16]\]. The present study confirmed that TCDD induces interferon-related genes in cells derived from human fetuses.

On the other hand, the up-regulation of glucose transporter genes was not observed in AEC culture by DNA microarray analysis (data are not shown), though they were strongly up-regulated in TCDD-treated rat placentas \[[@B16]\]. The placenta is the organ rich in blood vessels and it is reported that exposure to TCDD causes a hypoxic state in the placentas and the glucose kinetics are also altered in those organs \[[@B21],[@B22]\]. On the other hand, interferon is known to be involved in the regulation of angiogenesis. Mizutani et al speculated that the activation of the interferon signaling pathway impaired the angiogenesis in TCDD-treated rat placentas and brought about a hypoxic state in the placentas which up-regulated glucose transporter gene expression \[[@B16]\]. It was deduced that the expression of glucose transporter genes was not up-regulated in AEC, since both the control and TCDD-treated cells had an adequate supply of oxygen when in the *in vitro*culture condition. AEC cultures in the present study were performed under air conditions. In future studies, comparing TCDD-inducible genes between AEC cultures under hypoxic conditions and under air conditions would verify the inference and show which condition is closer to *in vivo*.

Although no changes in cellular morphology, number and viability were observed under the experimental conditions, it was an interesting observation that the expression of genes related to the synthesis and degradation of collagen, that is, MMP9, ITGA2 and ITGA10 were also up-regulated by TCDD in human AEC. Martinez JM et al reported the induction of MMP1, MMM9 and tissue inhibitor of metalloproteinase 3 in TCDD-treated human airway epithelial cells using microarray analysis in 2002 \[[@B23]\]. Thereafter, increased mRNA levels of MMPs were reported in TCDD-treated human cells, such as, MMP1 in keratinocytes \[[@B24]\] and melanoma cells \[[@B25]\], MMP2 in melanoma cells \[[@B25]\], MMP3 and MMP7 in endometrial cells \[[@B26]\], and MMP9 in prostate cancer cells \[[@B27]\] and melanoma cells \[[@B25]\]. Although the mechanisms of induction of MMP genes by TCDD are not fully clarified, Murphy et al reported that TCDD activation of MMP1 mRNA expression was mediated through increased promoter activity \[[@B24]\]. Villano CM et al reported aryl hydrocarbon receptor dependent MMP1, 2, and 9 expression by TCDD and speculated that MMP expression may be a common endpoint for activation of the aryl hydrocarbon receptor pathway \[[@B25]\]. It is speculated that TCDD caused pathological lesions by altering the expression of genes involved in matrix remodeling \[[@B24]\]. On the other hand, increased premature labor is reported in women exposed to dioxins in Chapaevsk \[[@B28]\]. The tensile strength of fetal membranes is provided almost exclusively by the amnion, and the interstitial collagens are believed to be the major source of the tensile strength of this tissue. AEC secrete not only collagens and noncollagenous glycoproteins but also MMPs \[[@B14]\]. Considering these biological characters of the amnion and the present observations on increased expression of genes related to the synthesis and degradation of collagens, our findings permit a better understanding of the pathology of premature labor by dioxins. The study of mechanisms on the induction of these genes by TCDD in human AEC would be the subject of future work.

The data of TCDD-inducible and -suppressive genes in human AEC culture is available at ED-Genes \[[@B29]\].

Conclusion
==========

We identified 38 TCDD-inducible genes in human AEC using DNA microarray and quantitative real-time PCR analyses. Interferon-inducible genes and genes related to collagen synthesis or degradation were up-regulated. These observations indicate that the comprehensive methods used in this study are useful in investigating the effects of dioxins on human feto-placenta.
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